Top

04-04-2024 | Cancer Therapy | REVIEW ARTICLE

In vivo safety evaluation method for nanomaterials for cancer therapy

Authors: Mengqi Chen, Jingyi Hei, Yan Huang, Xiyu Liu, Yong Huang

Published in: Clinical and Translational Oncology

Abstract

Nanomaterials are extensively used in the diagnosis and treatment of cancer and other diseases because of their distinctive physicochemical properties, including the small size and ease of modification. The approval of numerous nanomaterials for clinical treatment has led to a significant increase in human exposure to these materials. When nanomaterials enter organisms, they interact with DNA, cells, tissues, and organs, potentially causing various adverse effects, such as genotoxicity, reproductive toxicity, immunotoxicity, and damage to tissues and organs. Therefore, it is crucial to elucidate the side effects and toxicity mechanisms of nanomaterials thoroughly before their clinical applications. Although methods for in vitro safety evaluation of nanomaterials are well established, systematic methods for in vivo safety evaluation are still lacking. This review focuses on the in vivo safety evaluation of nanomaterials and explores their potential effects. In addition, the experimental methods for assessing such effects in various disciplines, including toxicology, pharmacology, physiopathology, immunology, and bioinformatics are also discussed.

Patel P, Shah J. Safety and toxicological considerations of nanomedicines: the future directions. Curr Clin Pharmacol. 2017. https://doi.org/10.2174/1574884712666170509161252.CrossRefPubMed

Sort J. Nanocomposite materials: a section of nanomaterials. Nanomaterials (Basel). 2022. https://doi.org/10.3390/nano12020203.CrossRefPubMed

Lamberti M, Zappavigna S, Sannolo N, Porto S, Caraglia M. Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers. Expert Opin Drug Deliv. 2014. https://doi.org/10.1517/17425247.2014.913568.CrossRefPubMed

Duncan R. Polymer therapeutics: top 10 selling pharmaceuticals – what next? J Control Release. 2014. https://doi.org/10.1016/j.jconrel.2014.05.001.CrossRefPubMed

Janrao C, Khopade S, Bavaskar A, Gomte SS, Agnihotri TG, Jain A. Recent advances of polymer based nanosystems in cancer management. J Biomater Sci Polym Ed. 2023. https://doi.org/10.1080/09205063.2022.2161780.CrossRefPubMed

Liyanage W, Wu T, Kannan S, Kannan RM. Dendrimer-siRNA conjugates for targeted intracellular delivery in glioblastoma animal models. ACS Appl Mater Interfaces. 2022. https://doi.org/10.1021/acsami.2c13129.CrossRefPubMed

Zhan M, Qiu J, Fan Y, Chen L, Guo Y, Wang Z, et al. Phosphorous dendron micelles as a nanomedicine platform for cooperative tumor chemoimmunotherapy via synergistic modulation of immune cells. Adv Mater. 2023. https://doi.org/10.1002/adma.202208277.CrossRefPubMed

Yang H, Wang Q, Li Z, Li F, Wu D, Fan M, et al. Hydrophobicity-adaptive nanogels for programmed anticancer drug delivery. Nano Lett. 2018. https://doi.org/10.1021/acs.nanolett.8b03828.CrossRefPubMedPubMedCentral

Yao J, Li T, Shi X, Wang Y, Fang S, Wang H. A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies. Acta Biomater. 2021. https://doi.org/10.1016/j.actbio.2021.05.047.CrossRefPubMed

10.

Zha J-W, Xiao M, Wan B, Wang X, Dang Z-M, Chen G. Polymer dielectrics for high-temperature energy storage: constructing carrier traps. Progress Mater Sci. 2023. https://doi.org/10.1016/j.pmatsci.2023.101208.CrossRef

11.

Chou TH, Chen SC, Chu IM. Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J Biosci Bioeng. 2003. https://doi.org/10.1016/S1389-1723(03)80076-2.CrossRefPubMed

12.

Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006. https://doi.org/10.1016/j.bbamem.2006.05.028.CrossRefPubMed

13.

Ye Z, Bao Y, Chen Z, Ye H, Feng Z, Li Y, et al. Recent advances in the metal/organic hybrid nanomaterials for cancer theranostics. Coordination Chem Rev. 2024. https://doi.org/10.1016/j.ccr.2023.215654.CrossRef

14.

Wuttke S, Zimpel A, Bein T, Braig S, Stoiber K, Vollmar A, et al. Validating metal-organic framework nanoparticles for their nanosafety in diverse biomedical applications. Adv Healthc Mater. 2017. https://doi.org/10.1002/adhm.201600818.CrossRefPubMed

15.

Cui L, Wang X, Sun B, Xia T, Hu S. Predictive metabolomic signatures for safety assessment of metal oxide nanoparticles. ACS Nano. 2019. https://doi.org/10.1021/acsnano.9b05793.CrossRefPubMedPubMedCentral

16.

Bagheri B, Surwase SS, Lee SS, Park H, Faraji Rad Z, Trevaskis NL, et al. Carbon-based nanostructures for cancer therapy and drug delivery applications. J Mater Chem B. 2022. https://doi.org/10.1039/d2tb01741e.CrossRefPubMed

17.

Rahamathulla M, Bhosale RR, Osmani RAM, Mahima KC, Johnson AP, Hani U, et al. Carbon nanotubes: current perspectives on diverse applications in targeted drug delivery and therapies. Materials (Basel). 2021. https://doi.org/10.3390/ma14216707.CrossRefPubMed

18.

Akhtar N, Pathak K. Carbon nanotubes in the treatment of skin cancers: safety and toxicological aspects. Pharm Nanotechnol. 2017. https://doi.org/10.2174/2211738505666170228132148.CrossRefPubMed

19.

Jogi H, Maheshwari R, Raval N, Kuche K, Tambe V, Mak KK, et al. Carbon nanotubes in the delivery of anticancer herbal drugs. Nanomedicine (Lond). 2018. https://doi.org/10.2217/nnm-2017-0397.CrossRefPubMed

20.

He C, Ruan F, Jiang S, Zeng J, Yin H, Liu R, et al. Black phosphorus quantum dots cause nephrotoxicity in organoids, mice, and human cells. Small. 2020. https://doi.org/10.1002/smll.202001371.CrossRefPubMed

21.

Allocca M, Mattera L, Bauduin A, Miedziak B, Moros M, De Trizio L, et al. An integrated multilevel analysis profiling biosafety and toxicity induced by indium- and cadmium-based quantum dots in vivo. Environ Sci Technol. 2019. https://doi.org/10.1021/acs.est.9b00373.CrossRefPubMed

22.

Tang AC, Hwang GL, Tsai SJ, Chang MY, Tang ZC, Tsai MD, et al. Biosafety of non-surface modified carbon nanocapsules as a potential alternative to carbon nanotubes for drug delivery purposes. PLoS ONE. 2012. https://doi.org/10.1371/journal.pone.0032893.CrossRefPubMedPubMedCentral

23.

Chen L, Zhang S, Duan Y, Song X, Chang M, Feng W, et al. Silicon-containing nanomedicine and biomaterials: materials chemistry, multi-dimensional design, and biomedical application. Chem Soc Rev. 2024. https://doi.org/10.1039/d1cs01022k.CrossRefPubMed

24.

Baati T, Al-Kattan A, Esteve MA, Njim L, Ryabchikov Y, Chaspoul F, et al. Ultrapure laser-synthesized Si-based nanomaterials for biomedical applications: in vivo assessment of safety and biodistribution. Sci Rep. 2016. https://doi.org/10.1038/srep25400.CrossRefPubMedPubMedCentral

25.

Liu J, Mu W, Gao T, Fang Y, Zhang N, Liu Y. CD13-Mediated pegylated carboxymethyl chitosan-capped mesoporous silica nanoparticles for enhancing the therapeutic efficacy of hepatocellular carcinoma. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15020426.CrossRefPubMedPubMedCentral

26.

Gribaldo L, Gennari A, Blackburn K, Clemedson C, Deguercy A, Meneguz A, et al. Acute toxicity. Altern Lab Anim. 2005. https://doi.org/10.1177/026119290503301s07.CrossRefPubMed

27.

He Z, Bao K, Jian J, Zhao Y, Jian Z, Hu C, et al. Biotin-targeted multifunctional nanoparticles encapsulating 10-hydroxycamptothecin and apoptin plasmid for synergistic hepatocellular carcinoma treatment. ACS Appl Polym Mater. 2022. https://doi.org/10.1021/acsapm.1c01393.CrossRef

28.

Gao W, Zhang J, Xue Q, Yin X, Yin X, Li C, et al. Acute and subacute toxicity study of graphene-based tumor cell nucleus-targeting fluorescent nanoprobes. Mol Pharm. 2020. https://doi.org/10.1021/acs.molpharmaceut.0c00380.CrossRefPubMedPubMedCentral

29.

Tutty MA, Vella G, Vennemann A, Wiemann M, Prina-Mello A. Evaluating nanobiomaterial-induced DNA strand breaks using the alkaline comet assay. Drug Deliv Transl Res. 2022. https://doi.org/10.1007/s13346-022-01178-7.CrossRefPubMedPubMedCentral

30.

Miyamae Y, Yamamoto M, Sasaki YF, Kobayashi H, Igarashi-Soga M, Shimoi K, et al. Evaluation of a tissue homogenization technique that isolates nuclei for the in vivo single cell gel electrophoresis (comet) assay: a collaborative study by five laboratories. Mutat Res. 1998. https://doi.org/10.1016/s1383-5718(98)00112-0.CrossRefPubMed

31.

Li L, Deng Y, Meng X, Chang H, Ling C, Li D, et al. Genotoxicity evaluation of silica nanoparticles in murine: a systematic review and meta-analysis. Toxicol Mech Methods. 2022. https://doi.org/10.1080/15376516.2021.1965277.CrossRefPubMed

32.

Chen B-A, Wu W-W, Cheng J, Wang J, Gao F, Xu W-L, et al. The biocompatibility and security of magnetic nanoparticles Fe₃O₄-DNR used in hematologic malignancies therapy. Blood. 2010. https://doi.org/10.1182/blood.V116.21.3970.3970.CrossRefPubMedPubMedCentral

33.

Wang X, Li T, Su X, Li J, Li W, Gan J, et al. Genotoxic effects of silver nanoparticles with/without coating in human liver HepG2 cells and in mice. J Appl Toxicol. 2019. https://doi.org/10.1002/jat.3779.CrossRefPubMedPubMedCentral

34.

Rizk MZ, Ali SA, Kadry MO, Fouad GI, Kamel NN, Younis EA, et al. C-reactive protein signaling and chromosomal abnormalities in nanotoxicity induced via different doses of TiO(2) (80 nm) boost liver function. Biol Trace Elem Res. 2020. https://doi.org/10.1007/s12011-020-02030-0.CrossRefPubMed

35.

Bryce SM, Bemis JC, Dertinger SD. In vivo mutation assay based on the endogenous Pig-a locus. Environ Mol Mutagen. 2008. https://doi.org/10.1002/em.20379.CrossRefPubMed

36.

Gollapudi BB, Lynch AM, Heflich RH, Dertinger SD, Dobrovolsky VN, Froetschl R, et al. The in vivo Pig-a assay: a report of the International Workshop On Genotoxicity Testing (IWGT) workgroup. Mutat Res Genet Toxicol Environ Mutagen. 2015. https://doi.org/10.1016/j.mrgentox.2014.09.007.CrossRefPubMed

37.

Raschke M, Igl BW, Kenny J, Collins J, Dertinger SD, Labash C, et al. In vivo Pig-a gene mutation assay: guidance for 3Rs-friendly implementation. Environ Mol Mutagen. 2016. https://doi.org/10.1002/em.22060.CrossRefPubMed

38.

Itoh S, Hattori C, Nakayama S, Hanamoto A. PIGRET assay can detect mutagenicity of ethyl methanesulfonate much earlier than RBC Pig-a assay. Mutat Res Genet Toxicol Environ Mutagen. 2016. https://doi.org/10.1016/j.mrgentox.2015.11.010.CrossRefPubMed

39.

Yamamoto M, Wakata A. Evaluation of in vivo gene mutation with etoposide using Pig-a and PIGRET assays. Mutat Res/Genetic Toxicol Environ Mutagenesis. 2016. https://doi.org/10.1016/j.mrgentox.2016.06.006.CrossRef

40.

Onoue S, Yamada S, Chan HK. Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine. 2014. https://doi.org/10.2147/ijn.S38378.CrossRefPubMedPubMedCentral

41.

Chen J, Ning E, Wang Z, Jing Z, Wei G, Wang X, et al. Docetaxel loaded mPEG-PLA nanoparticles for sarcoma therapy: preparation, characterization, pharmacokinetics, and anti-tumor efficacy. Drug Deliv. 2021. https://doi.org/10.1080/10717544.2021.1945167.CrossRefPubMedPubMedCentral

42.

Bassiony H, El-Ghor AA, Salaheldin TA, Sabet S, Mohamed MM. Tissue distribution, histopathological and genotoxic effects of magnetite nanoparticles on ehrlich solid carcinoma. Biol Trace Elem Res. 2022. https://doi.org/10.1007/s12011-022-03102-z.CrossRefPubMedPubMedCentral

43.

Abdullah Al N, Lee JE, In I, Lee H, Lee KD, Jeong JH, et al. Target delivery and cell imaging using hyaluronic acid-functionalized graphene quantum dots. Mol Pharm. 2013. https://doi.org/10.1021/mp400219u.CrossRef

44.

Salimi M, Sarkar S, Fathi S, Alizadeh AM, Saber R, Moradi F, et al. Biodistribution, pharmacokinetics, and toxicity of dendrimer-coated iron oxide nanoparticles in BALB/c mice. Int J Nanomedicine. 2018. https://doi.org/10.2147/ijn.S157293.CrossRefPubMedPubMedCentral

45.

Abdel Fadeel DA, Kamel R, Fadel M. PEGylated lipid nanocarrier for enhancing photodynamic therapy of skin carcinoma using curcumin: in-vitro/in-vivo studies and histopathological examination. Sci Rep. 2020. https://doi.org/10.1038/s41598-020-67349-z.CrossRefPubMedPubMedCentral

46.

Boraschi D, Costantino L, Italiani P. Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. Nanomedicine (Lond). 2012. https://doi.org/10.2217/nnm.11.169.CrossRefPubMed

47.

Marxfeld HA, Küttler K, Dammann M, Gröters S, van Ravenzwaay B. Variance of body and organ weights in 28-day studies in mice. Regul Toxicol Pharmacol. 2019. https://doi.org/10.1016/j.yrtph.2019.104472.CrossRefPubMed

48.

Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, et al. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci. 2003. https://doi.org/10.1093/toxsci/kfg188.CrossRefPubMed

49.

Lappin PB, Black LE. Immune modulator studies in primates: the utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity. Toxicol Pathol. 2003. https://doi.org/10.1080/01926230390174986.CrossRefPubMed

50.

Grote-Wessels S, Frings W, Smith CA, Weinbauer GF. Immunotoxicity testing in nonhuman primates. Methods Mol Biol. 2010. https://doi.org/10.1007/978-1-60761-401-2_23.CrossRefPubMed

51.

Hong F, Zhou Y, Zhou Y, Wang L. Immunotoxic effects of thymus in mice following exposure to nanoparticulate TiO(2). Environ Toxicol. 2017. https://doi.org/10.1002/tox.22439.CrossRefPubMed

52.

Dietert RR, Bunn TL, Lee JE. The delayed type hypersensitivity assay using protein and xenogeneic cell antigens. Methods Mol Biol. 2010. https://doi.org/10.1007/978-1-60761-401-2_13.CrossRefPubMed

53.

Weaver JL, Chapdelaine JM, Descotes J, Germolec D, Holsapple M, House R, et al. Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions. J Immunotoxicol. 2005. https://doi.org/10.1080/15476910590930100.CrossRefPubMed

54.

Naz F, Dinda AK, Saxena R, Koul V. Biosafety of unmodified ultrafine gold particles (AuPs) upon interacting with human blood components before systemic use. Regul Toxicol Pharmacol. 2019. https://doi.org/10.1016/j.yrtph.2019.104405.CrossRefPubMed

55.

Ghiasvand Mohammadkhani L, Khoshkam M, Kompany-Zareh M, Amiri M, Ramazani A. Metabolomics approach to study in vivo toxicity of graphene oxide nanosheets. J Appl Toxicol. 2022. https://doi.org/10.1002/jat.4235.CrossRefPubMed

56.

Kim YJ, Rahman MM, Lee SM, Kim JM, Park K, Kang JH, et al. Assessment of in vivo genotoxicity of citrated-coated silver nanoparticles via transcriptomic analysis of rabbit liver tissue. Int J Nanomedicine. 2019. https://doi.org/10.2147/ijn.S174515.CrossRefPubMedPubMedCentral

57.

Liu T, Wang J, Xie Z, Wan L, Xiang J, Zhang Y, et al. Batch preparation of gold nanoparticles with highly uniform morphology and tunable plasmonic properties. Nanotechnology. 2020. https://doi.org/10.1088/1361-6528/ab9bd1.CrossRefPubMed

58.

Zhang J, Lin J, Song HS, Elssfah EM, Liu SJ, Luo JJ, et al. Bulk-quantity fast production of Al₄B₂O₉/Al₁₈B₄O₃₃ single-crystal nanorods by a novel technique. Mater Lett. 2006. https://doi.org/10.1016/j.matlet.2006.03.006.CrossRef

59.

Rodríguez-Carrillo C, Torres García J, Benítez M, El Haskouri J, Amorós P, Ros-Lis JV. Batch and flow synthesis of CeO(2) nanomaterials using solid-state microwave generators. Molecules. 2022. https://doi.org/10.3390/molecules27092712.CrossRefPubMedPubMedCentral

60.

Hassane Hamadou A, Huang W-C, Xue C, Mao X. Formulation of vitamin C encapsulation in marine phospholipids nanoliposomes: characterization and stability evaluation during long term storage. LWT. 2020. https://doi.org/10.1016/j.lwt.2020.109439.CrossRef

61.

Kaur A, Darvill D, Xiang S, Heng JYY, Petrov PK, Hoye RLZ, et al. Development of nanopackaging for storage and transport of loaded lipid nanoparticles. Nano Lett. 2023. https://doi.org/10.1021/acs.nanolett.3c01271.CrossRefPubMedPubMedCentral

62.

Fröhlich E. Comparison of conventional and advanced in vitro models in the toxicity testing of nanoparticles. Artif Cells Nanomed Biotechnol. 2018. https://doi.org/10.1080/21691401.2018.1479709.CrossRefPubMedPubMedCentral

63.

Pensado-López A, Fernández-Rey J, Reimunde P, Crecente-Campo J, Sánchez L, Torres AF. Zebrafish models for the safety and therapeutic testing of nanoparticles with a focus on macrophages. Nanomaterials (Basel). 2021. https://doi.org/10.3390/nano11071784.CrossRefPubMed

64.

Chen L, Sun T, Lv Y, Lu X, Li X, Zhang H, et al. Efficacy, mechanism, and safety of melatonin-loaded on thermosensitive nanogels for rabbit VX2 tumor embolization: a novel design. J Pineal Res. 2023. https://doi.org/10.1111/jpi.12900.CrossRefPubMed

65.

Zhu H, Zhu Z, Hao J, Sun S, Lu S, Wang C, et al. High-entropy alloy stabilized active Ir for highly efficient acidic oxygen evolution. Chem Eng J. 2022. https://doi.org/10.1016/j.cej.2021.133251.CrossRefPubMedPubMedCentral

66.

Dan P, Senthilkumar S, Gopinath DV, Mohideen SS. Safety studies of polyethylene glycol–hydroxyapatite nanocomposites on Drosophila melanogaster: an in vivo model. Appl Nanosci. 2022. https://doi.org/10.1007/s13204-021-02284-7.CrossRef

67.

Zielińska A, Costa B, Ferreira MV, Miguéis D, Louros JMS, Durazzo A, et al. Nanotoxicology and nanosafety: safety-by-design and testing at a glance. Int J Environ Res Public Health. 2020. https://doi.org/10.3390/ijerph17134657.CrossRefPubMedPubMedCentral

68.

Chrishtop VV, Prilepskii AY, Nikonorova VG, Mironov VA. Nanosafety vs. nanotoxicology: adequate animal models for testing in vivo toxicity of nanoparticles. Toxicology. 2021. https://doi.org/10.1016/j.tox.2021.152952.

69.

Kishor K, Sahu RK. Biomarkers and their applications in toxicology. Lab Anim. 2016. https://doi.org/10.1038/laban.954.CrossRef

70.

Lérida-Viso A, Estepa-Fernández A, García-Fernández A, Martí-Centelles V, Martínez-Máñez R. Biosafety of mesoporous silica nanoparticles; towards clinical translation. Adv Drug Deliv Rev. 2023. https://doi.org/10.1016/j.addr.2023.115049.CrossRefPubMed

71.

Bastús NG, Puntes V. Nanosafety: towards safer nanoparticles by design. Curr Med Chem. 2018. https://doi.org/10.2174/0929867324666170413124915.CrossRefPubMed

72.

Csóka I, Ismail R, Jójárt-Laczkovich O, Pallagi E. Regulatory considerations, challenges and risk-based approach in nanomedicine development. Curr Med Chem. 2021. https://doi.org/10.2174/0929867328666210406115529.CrossRefPubMed

73.

Chen Z, Yue Z, Wang R, Yang K, Li S. Nanomaterials: a powerful tool for tumor immunotherapy. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.979469.CrossRefPubMedPubMedCentral

74.

Choi KY, Han HS, Lee ES, Shin JM, Almquist BD, Lee DS, et al. Hyaluronic acid-based activatable nanomaterials for stimuli-responsive imaging and therapeutics: beyond CD44-mediated drug delivery. Adv Mater. 2019. https://doi.org/10.1002/adma.201803549.CrossRefPubMedPubMedCentral

75.

Delfi M, Sartorius R, Ashrafizadeh M, Sharifi E, Zhang Y, De Berardinis P, et al. Self-assembled peptide and protein nanostructures for anti-cancer therapy: targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today. 2021. https://doi.org/10.1016/j.nantod.2021.101119.CrossRefPubMedPubMedCentral

76.

Mohamed HRH, Welson M, Yaseen AE, El-Ghor A. Induction of chromosomal and DNA damage and histological alterations by graphene oxide nanoparticles in Swiss mice. Drug Chem Toxicol. 2021. https://doi.org/10.1080/01480545.2019.1643876.CrossRefPubMed

77.

Wan R, Mo Y, Zhang Z, Jiang M, Tang S, Zhang Q. Cobalt nanoparticles induce lung injury, DNA damage and mutations in mice. Part Fibre Toxicol. 2017. https://doi.org/10.1186/s12989-017-0219-z.CrossRefPubMedPubMedCentral

78.

Ali D, Falodah FA, Almutairi B, Alkahtani S, Alarifi S. Assessment of DNA damage and oxidative stress in juvenile Channa punctatus (Bloch) after exposure to multi-walled carbon nanotubes. Environ Toxicol. 2020. https://doi.org/10.1002/tox.22871.CrossRefPubMed

79.

Kozics K, Sramkova M, Kopecka K, Begerova P, Manova A, Krivosikova Z, et al. Pharmacokinetics, biodistribution, and biosafety of PEGylated gold nanoparticles in vivo. Nanomaterials (Basel). 2021. https://doi.org/10.3390/nano11071702.CrossRefPubMedPubMedCentral

80.

Bulcão RP, de Freitas FA, Dallegrave E, Venturini CG, Baierle M, Durgante J, et al. In vivo toxicological evaluation of polymeric nanocapsules after intradermal administration. Eur J Pharm Biopharm. 2014. https://doi.org/10.1016/j.ejpb.2013.04.001.CrossRefPubMed

81.

Zhanataev AK, Anisina EA, Kulakova AV, Shilovskiy IP, Lisitsyn AA, Koloskova OO, et al. Genotoxicity of cationic lipopeptide nanoparticles. Toxicol Lett. 2020. https://doi.org/10.1016/j.toxlet.2020.04.011.CrossRefPubMed

82.

Jalili P, Huet S, Lanceleur R, Jarry G, Le Hegarat L, Nesslany F, et al. Genotoxicity of aluminum and aluminum oxide nanomaterials in rats following oral exposure. Nanomaterials (Basel). 2020. https://doi.org/10.3390/nano10020305.CrossRefPubMed

83.

Salman AS, Alkhatib SN, Ahmed FM, Hamouda RA. Chitosan nanoparticles loaded with capparis cartilaginea decne extract: insights into characterization and antigenotoxicity in vivo. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15112551.CrossRefPubMedPubMedCentral

84.

Wen H, Dan M, Yang Y, Lyu J, Shao A, Cheng X, et al. Acute toxicity and genotoxicity of silver nanoparticle in rats. PLoS ONE. 2017. https://doi.org/10.1371/journal.pone.0185554.CrossRefPubMedPubMedCentral

85.

Fatima R, Ahmad R. Hepatotoxicity and chromosomal abnormalities evaluation due to single and repeated oral exposures of chromium oxide nanoparticles in Wistar rats. Toxicol Ind Health. 2019. https://doi.org/10.1177/0748233719863632.CrossRefPubMed

86.

Villani P, Eleuteri P, Pacchierotti F, Maranghi F, Tassinari R, Narciso L, et al. Pyrogenic synthetic amorphous silica (NM-203): genotoxicity in rats following sub-chronic oral exposure. Mutat Res Genet Toxicol Environ Mutagen. 2022. https://doi.org/10.1016/j.mrgentox.2022.503458.CrossRefPubMed

87.

Ates F, Akyol I, Soydan H. Re: Meelan Bul, Xiaoye Zhu, Antti Rannikko, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol. 2012. https://doi.org/10.1016/j.eururo.2012.04.001.

88.

Wang D, Dan M, Ji Y, Wu X, Xu L, Wen H. Single-dosed genotoxicity study of gold nanorod core/silver shell nanostructures by Pig-a, micronucleus, and comet assays. J Biomed Nanotechnol. 2018. https://doi.org/10.1166/jbn.2018.2640.CrossRefPubMed

89.

Zheng C, Tian X, Cai J, Huang L, Wang S, Yang F, et al. In vivo immunotoxicity of Gd(2) O(3):Eu(3+) nanoparticles and the associated molecular mechanism. J Biochem Mol Toxicol. 2020. https://doi.org/10.1002/jbt.22562.CrossRefPubMed

90.

Easo SL, Mohanan PV. In vitro hematological and in vivo immunotoxicity assessment of dextran stabilized iron oxide nanoparticles. Colloids Surf B Biointerfaces. 2015. https://doi.org/10.1016/j.colsurfb.2015.06.046.CrossRefPubMed

91.

Lee S, Kim MS, Lee D, Kwon TK, Khang D, Yun HS, et al. The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice. Int J Nanomedicine. 2013. https://doi.org/10.2147/ijn.S39534.CrossRefPubMedPubMedCentral

92.

Li X, Wang L, She L, Sun L, Ma Z, Chen M, et al. Immunotoxicity assessment of ordered mesoporous carbon nanoparticles modified with PVP/PEG. Colloids Surf B Biointerfaces. 2018. https://doi.org/10.1016/j.colsurfb.2018.07.072.CrossRefPubMedPubMedCentral

93.

Kauffman KJ, Mir FF, Jhunjhunwala S, Kaczmarek JC, Hurtado JE, Yang JH, et al. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials. 2016. https://doi.org/10.1016/j.biomaterials.2016.09.006.CrossRefPubMedPubMedCentral

Title: In vivo safety evaluation method for nanomaterials for cancer therapy
Authors: Mengqi Chen
Jingyi Hei
Yan Huang
Xiyu Liu
Yong Huang
Publication date: 04-04-2024
Publisher: Springer International Publishing
Keyword: Cancer Therapy
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-024-03466-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer